3 news items
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
benefits of any of the Company's products or product candidates for any specific disease indication or at any dosage, including the potential
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
to benefit from therapy. "Access to IMCIVREE in England and Wales is an important milestone in our global efforts to bring this medicine
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
biotech sector continues to benefit from favorable financing conditions and a vibrant outlook for mergers and acquisitions, coupled with innovative
- Prev
- 1
- Next